Gynecologic Cancer Steering Committee
The NCI Gynecologic Cancer Steering Committee (GCSC) was transitioned into a NCI Disease Specific Steering Committee from the Gynecologic Cancer Intergroup in May 2006. The GCSC is currently composed of the Steering Committee and three specific disease-site task forces. Members of the GCSC include Cooperative Group gynecologic disease committee chairs, Specialized Programs of Research Excellence (SPOREs), Cancer Center, and R01/P01 investigators along with community oncologists, biostatistician(s), patient advocates, and NCI staff.
Mission Statement
The GCSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in gynecologic cancer clinical research by addressing the design and prioritization of phase III trials and evaluating randomized phase II studies. As part of its mission, this GCSC is intent on fostering collaboration with international groups and institutions engaged in conducting trials in gynecologic cancers.
Roster of Gynecologic Cancer Steering Committee (GCSC) members
Michael J. Birrer, M.D., Ph.D., David M. Gershenson, M.D., and Gillian M. Thomas, M.D., Co-chairs
Task Forces
- Cervical Cancer: Alan Covens, M.D., and Don S. Dizon, M.D., Co-chairs
- Ovarian Cancer: Carol Aghajanian, M.D., and Benjamin E. Greer, M.D., Co-chairs
- Uterine Cancer: Martee Hensley, M.D., and Scott McMeekin, M.D., Co-chairs
Clinical Trial Planning Meetings (CTPMs): Goal of Clinical Trial Planning Meetings, and List of CTPM Executive Summaries and Publications
Active Protocols
- GOG-0240: Phase III Randomized Study of Paclitaxel in Combination With Cisplatin or Topotecan Hydrochloride With Versus Without Bevacizumab in Patients With Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix (NCT00803062)
Active Activation date: 4/6/2009
- GOG-0249: Phase III Randomized Study of Pelvic Radiotherapy Versus Vaginal Cuff Brachytherapy, Paclitaxel, and Carboplatin in Patients With High-Risk Stage I or II Endometrial Carcinoma (NCT00807768)
Activation date: 3/23/2009
- GOG-0248: Phase II Randomized Study of Temsirolimus With or Without Hormonal Therapy Comprising Megestrol Acetate and Tamoxifen Citrate in Patients With Advanced, Persistent, or Recurrent Endometrial Carcinoma (NCT00729586)
Activation date: 9/29/2008
- GOG-0238: Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer (NCT00492778)
Activation date: 2/25/2008
- GOG-0213: Phase III Randomized Study of Adjuvant Chemotherapy Comprising Carboplatin and Paclitaxel With Versus Without Bevacizumab and/or Secondary Cytoreduction Surgery in Patients With Platinum-Sensitive Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (NCT00565851)
Activation date: 12/6/2007
- GOG-0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma (NCT00942357)
Activation date: 06/29/2009
- GOG-0261: Randomized Phase III Trial of Carboplatin plus Paclitaxel versus Ifosfamide plus Taxol in Patients with Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus (NCT00954174)
Activation date: 08/17/2009
- GOG-0252: Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma (NCT00951496)
Activation date: 07/27/2009
- RTOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy (NCT00980954)
Activation date: 09/16/2009
- GOG-0255: A Randomized Phase III Trial in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer with a Polyvalent Vaccine-KLH Conjugate + QS-21 versus QS-21 (NCT00857545)
Activation date: 07/26/2010
- GOG-0250: Randomized Phase IIB Evaluation of Gemcitabine-Docetaxel with or without Bevacizumab for Advanced or Recurrent Uterine Leiomyosarcoma (NCT01012297)
Activation date: 11/09/2009
- GOG-0263: Randomized Clinical Trial for Adjuvant Chemo-radiation in Post-operative Cervical Cancer Patients with Intermediate Risk Factors (NCT01101451)
Activation date: 04/12/2010
- GOG-0264: A Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage Sex Cord-Stromal Tumors of the Ovary (NCT01042522)
Activation date: 02/08/2010
- SWOG-S0904: Randomized Phase II Study of Docetaxel Followed by ZD6474 (Vandetanib) vs. Docetaxel plus ZD6474 in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (NCT00872989)
Activation date: 03/15/2010
- GOG-0262: A Randomized Phase III Trial of Every-Three-Weeks versus Dose Dense Weekly Paclitaxel and Carboplatin plus Concurrent Bevacizumab in the Treatment of Primary Suboptimal Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma (NCT01167712)
Activation date: 09/27/2010
- GOG-0241:A Randomized Phase III Evaluation of Capecitabine and Oxaliplatin (Xelox) versus Carboplatin and Paclitaxel in Mucinous Adenocarcinoma of the Ovary (NCT01081262)
Activation date: 10/12/2010
To search all active clinical trials, go to: http://www.cancer.gov/clinicaltrials/search
Publications
- Kitchner, H. C. and Trimble, E.L. Endometrial Cancer State of the Science Meeting . Int J Gynecol Cancer, 2009;19:134-140.
- Trimble, E. L. (for the Cervical SOTS writing Committee). Cervical Cancer State-of-the-Clinical-Science Meeting on Pretreatment Evaluation and Prognostic Factors, September 27-28, 2007: Proceedings and Recommendations. Gynecol Oncol, accepted for publication.
CCCT Contact: Jean M. Lynn, RN, MPH, OCN